Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Actavis Group has received two separate approvals from the FDA to market Bupropion Hydrochloride extended-release tablets. Distribution of the products will commence immediately.
Subscribe to our email newsletter
Bupropion Hydrochloride extended-release tablets (SR), available in 150mg strength, are the generic equivalent of Wellbutrin SR and are indicated for the treatment of major depressive disorder.
Bupropion Hydrochloride extended-release tablets (SR), available in 150mg strength, are the generic equivalent of Zyban and are indicated as an aid to smoking cessation treatment.
Terry Fullem, vice president of marketing and portfolio in US at Actavis, said: “These approvals further enhance our strength in the area of modified release products and provide valuable options to our customers and patients.”